Figure 4: (a) Normal control group (normal appearance of hepatocytes and cords, no fatty degeneration, and no necrosis). (b) Cisplatin (7.5 mg/kg) control group (fatty degeneration and necrosis, inflammatory infiltration, and enlarged vacuolations). (c) Daidzein (20 mg/kg) low-dose group (mild inflammation, slight fatty degeneration, and less vacuolations in cytoplasm). (d) Daidzein (40 mg/kg) high-group (cytoplasm well maintained, no inflammation, and very few fatty degenerations)